Itomed

Itopride Hydrochloride, the active ingredient in Itomed, is a prokinetic presented as an oral tablet for oral use. It enhances gastrointestinal motility and is used to relieve symptoms of functional dyspepsia, gastroesophageal reflux disease, and post‑prandial fullness in adult patients.

GNH USA supplies Itomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution.

Itopride Hydrochloride is a prokinetic agent that improves upper‑gastrointestinal motility and is indicated for several functional digestive disorders.

- Functional dyspepsia: reduces epigastric pain, early satiety and post‑prandial fullness. - Gastroesophageal reflux disease (GERD): alleviates reflux symptoms by promoting gastric emptying. - Postprandial fullness: diminishes the sensation of excessive fullness after meals.

Adverse reactions to Itomed are generally mild, but serious events can occur.

Common Side Effects: - Nausea - Dry mouth - Abdominal discomfort - Headache - Dizziness - Diarrhea

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia, tremor) - Severe allergic reactions, including anaphylaxis - Cardiac arrhythmias - Hepatic dysfunction - Neutropenia

Before prescribing Itomed, clinicians should consider several safety aspects.

- Assess renal and hepatic function: evaluate baseline organ status. - Use with caution in elderly patients: monitor for increased sensitivity. - Avoid in patients with known hypersensitivity to itopride or excipients. - Monitor for extrapyramidal symptoms during therapy. - Store at room temperature: keep in the original packaging, protect from moisture.

Itomed may interact with other medicines; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Concomitant use with strong anticholinergic agents may diminish prokinetic effect. - Co‑administration with other dopamine antagonists can increase risk of extrapyramidal reactions.

Moderate Interactions (Monitor Closely): - Antacids may reduce absorption; separate dosing by at least 2 hours. - CYP3A4 substrates could have altered plasma levels; monitor therapeutic response. - Non‑steroidal anti‑inflammatory drugs may increase gastrointestinal irritation; observe for symptoms.